Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

CureVac-GSK coronavirus variant vaccine generates good immune response in rats

Published 17/05/2021, 08:59
Updated 17/05/2021, 09:01
© Reuters. FILE PHOTO: German biotechnology company CureVac's vaccination against the coronavirus disease (COVID-19) is given to a volunteer at the start of a clinical test series in Tuebingen, Germany, June 22, 2020.   REUTERS/Kai Pfaffenbach/File Photo/File Photo

© Reuters. FILE PHOTO: German biotechnology company CureVac's vaccination against the coronavirus disease (COVID-19) is given to a volunteer at the start of a clinical test series in Tuebingen, Germany, June 22, 2020. REUTERS/Kai Pfaffenbach/File Photo/File Photo

By Alistair Smout

LONDON (Reuters) - A second-generation COVID-19 vaccine developed by CureVac and GlaxoSmithKline, designed to protect against coronavirus variants, produced a high level of immune response in a trial in rats, the companies said on Thursday.

CureVac in February said it would team up with GlaxoSmithKline on a COVID-19 vaccine aimed at targeting several variants with one shot.

The shot uses messenger RNA technology, similar to successful vaccines made by Pfizer-BioNTech and Moderna (NASDAQ:MRNA), and clinical trials of the shot in humans are expected to start in the third quarter of this year.

The mRNA "backbone" of the shot differs from CureVac's first COVID-19 vaccine candidate, and it is designed to work well at lower doses.

Rats immunised with the shot, called CV2CoV, showed quick, strong immune responses, the companies said, and blood serum "showed significant cross-neutralization against variants first discovered in Denmark (B.1.1.298), the UK (B.1.1.7) and South Africa (B.1.351)."

"To successfully fight the COVID-19 pandemic in the long term, we will need different vaccines and we need to be able to respond effectively to emerging variants," GSK Global Vaccines President Roger Connor said.

"We are pleased with these pre-clinical results as they show the potential of the next generation mRNA technology we are developing together with CureVac."

Although human trials are yet to start, these results mark a boost for GSK, the world's largest vaccine maker by sales.

GSK's collaboration with CureVac is a fresh attempt to play a major role in fighting the pandemic after a COVID-19 shot with Sanofi (PA:SASY) ran into delays and a collaboration with China's Clover Biopharmaceuticals was ended.

© Reuters. FILE PHOTO: German biotechnology company CureVac's vaccination against the coronavirus disease (COVID-19) is given to a volunteer at the start of a clinical test series in Tuebingen, Germany, June 22, 2020.   REUTERS/Kai Pfaffenbach/File Photo/File Photo

GSK, which acquired a 10% stake in CureVac last year, will also support the production of up to 100 million doses of CureVac's first-generation COVID-19 vaccine candidate.

CureVac's first generation COVID-19 vaccine is already in late-stage clinical trials.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.